{"id":87586,"date":"2024-07-25T12:18:39","date_gmt":"2024-07-25T12:18:39","guid":{"rendered":"https:\/\/mtctheme.medicaltourismco.com\/?p=87586"},"modified":"2024-08-22T09:51:09","modified_gmt":"2024-08-22T09:51:09","slug":"immunotherapy-for-ovarian-cancer-in-india","status":"publish","type":"post","link":"https:\/\/mtctheme.medicaltourismco.com\/immunotherapy-for-ovarian-cancer-in-india\/","title":{"rendered":"Immunotherapy for Ovarian Cancer in India"},"content":{"rendered":"


\n\tmtctheme_featured_post = “off”
\n\t\t\tmtctheme_title = “Immunotherapy for Ovarian Cancer in India: Find Costs, Hospitals & Success Rate”
\n\t\t\tmtctheme_pagemenu = [
\n {
\n “text”: “Cost”,
\n “url”: “#cost”
\n },
\n {
\n “text”: “Overview”,
\n “url”: “#overview”
\n },
\n {
\n “text”: “Procedure”,
\n “url”: “#procedure”
\n },
\n {
\n “text”: “Success Rate”,
\n “url”: “#success_rate”
\n },
\n {
\n “text”: “Hospitals”,
\n “url”: “#hospitals”
\n },
\n {
\n “text”: “Specialists”,
\n “url”: “#specialists”
\n },
\n {
\n “text”: “Why MTC?”,
\n “url”: “#why_mtc”
\n },
\n {
\n “text”: “FAQs”,
\n “url”: “#faqs”
\n },
\n {
\n “text”: “”,
\n “url”: “”
\n }
\n]
\n\t\t\tmtctheme_proscons1 = [
\n {
\n “pro”: “”,
\n “con”: “”
\n },
\n {
\n “pro”: “”,
\n “con”: “”
\n }
\n]
\n\t\t\tmtctheme_proscons2 = [
\n {
\n “pro”: “”,
\n “con”: “”
\n },
\n {
\n “pro”: “”,
\n “con”: “”
\n }
\n]
\n\t\t\tmtctheme_proscons3 = [
\n {
\n “pro”: “”,
\n “con”: “”
\n },
\n {
\n “pro”: “”,
\n “con”: “”
\n }
\n]
\n\t\t\tmtctheme_proscons4 = [
\n {
\n “pro”: “”,
\n “con”: “”
\n },
\n {
\n “pro”: “”,
\n “con”: “”
\n }
\n]
\n\t\t\tmtctheme_proscons5 = [
\n {
\n “pro”: “”,
\n “con”: “”
\n },
\n {
\n “pro”: “”,
\n “con”: “”
\n }
\n]
\n\t\t\tmtctheme_proscons6 = [
\n {
\n “pro”: “”,
\n “con”: “”
\n },
\n {
\n “pro”: “”,
\n “con”: “”
\n }
\n]
\n\t\t\tmtctheme_content = “

Cost<\/a>Overview<\/a>Procedure<\/a>Success Rate<\/a>Hospitals<\/a>Specialists<\/a>Why MTC?<\/a>FAQs<\/a><\/div>rnrn

Tired of persistent abdominal pain? Immunotherapy for ovarian cancer in India<\/strong> offers a safe & reliable option to fight cancer.<\/p>\n

Read more to find costs, top hospitals & doctors.<\/p>\n<\/div>rnrn\n

What Is the Cost of Immunotherapy for Ovarian Cancer in India?<\/h2>\n rnrnThe cost of immunotherapy for ovarian cancer in India starts at $1,200<\/strong> and can go upto $85,000<\/strong> for advanced therapy like CAR T-cell<\/strong>.rnrnrnIn the US, these treatments start from $15,000<\/strong> and can exceed $400,000. <\/strong>Therefore,u00a0making India a much more affordable option.rnrnHereu2019s a table that shows the different types of immunotherapies and their costs:rn<\/p>\n\nrn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\n
Cost of Immunotherapy for Ovarian Cancer in India<\/strong><\/caption>\n

rn<\/p>\n

Type of Immunotherapy<\/th>\n

rn<\/p>\n

About the immunotherapy<\/th>\n

rn<\/p>\n

Cost in India in USD<\/th>\n

rn<\/p>\n

Cost in the US in USD<\/th>\n

rn<\/tr>\n

rn<\/p>\n

Non-Specific Immunotherapy<\/td>\n

rn<\/p>\n

Administering general drugs to increase the immune system<\/td>\n

rn<\/p>\n

Starts at $1,200<\/strong><\/td>\n

rn<\/p>\n

Ranges between $15,000<\/strong>\n

Wellcome<\/p>\n

More people should have access to monoclonal antibodies. Covid-19 can make that happen<\/strong><\/p>\n

'The average treatment in the US can cost between $15,000 and $200,000 per year.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[1]<\/sup><\/span>u00a0- $30,000\n

JAMA Network<\/p>\n

Estimated Costs and Long-term Outcomes of Patients With High-Risk Nonu2013Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guu00e9rin in the Veterans Affairs Health System<\/strong><\/p>\n

'Total median costs at 1 year from the start of BCG induction therapy were $29u202f459 (IQR, $14u202f991-$52u202f060); 2 years, $55u202f267 (IQR, $28u202f667-$99u202f846); and 5 years, $117u202f361 (IQR, $59u202f680-$211u202f298).'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[2]<\/sup><\/span><\/strong><\/td>\n

rn<\/tr>\n

rn<\/p>\n

Monoclonal Antibodies<\/td>\n

rn<\/p>\n

Man-made proteins that are inserted in the body to act like antibodies<\/td>\n

rn<\/p>\n

$1,500<\/strong> \n

Times of India<\/p>\n

Monoclonal therapy a hit despite price | Hyderabad News<\/strong><\/p>\n

'A box now costs a minimum of Rs 1.2 lakh, with each dose costing Rs 60,000.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[3]<\/sup><\/span><\/td>\n

rn<\/p>\n

Over $100,000\n

PubMed<\/p>\n

Pricing of monoclonal antibody therapies: higher if used for cancer?<\/strong><\/p>\n

'After adjusting for factors that can affect production costs, the annual price of oncology or hematology mAbs was $149,622 higher than those used in cardiovascular or metabolic disorders; $98,981 higher than in immunology; $128,856 higher than in infectious diseases or allergy; and $106,830 higher than in ophthalmology (all P <.001).'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[4]<\/sup><\/span><\/strong><\/td>\n

rn<\/tr>\n

rn<\/p>\n

Immune Checkpoint Inhibitors<\/td>\n

rn<\/p>\n

Medication boosts the immune system by removing all checkpoints in fighting cancer<\/td>\n

rn<\/p>\n

$82,000<\/strong><\/td>\n

rn<\/p>\n

$250,000\n

NCBI<\/p>\n

The future of affordable cancer immunotherapy<\/strong><\/p>\n

'The average cost of cancer drugs increased from $50,000 per patient in the mid-1990s to $250,000.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[6]<\/sup><\/span><\/strong><\/td>\n

rn<\/tr>\n

rn<\/p>\n

T-cell Therapy (CAR T-cell therapy)<\/td>\n

rn<\/p>\n

Use of a part of patientu2019s white blood cells to fight cancer by modifying them in a lab<\/td>\n

rn<\/p>\n

$50,000 – $85,000<\/strong><\/td>\n

rn<\/p>\n

Over $400,000<\/strong>\n

ASCOpubs<\/p>\n

High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions<\/strong><\/p>\n

'As we sit on the precipice of a cellular therapy revolution in oncology, the high cost of CAR T-cell therapiesu2014typically over $400,000 USD and sometimes over $1 million USD per patient20,21u2014and their logistical challenges raise concerns about their affordability and access for patients, payers, and health care systems both in the United States and globally.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[7]<\/sup><\/span><\/td>\n

rn<\/tr>\n

rn<\/tbody>\n

rn<\/table>\n

rn<\/p>\n

*Prices are case-dependent.<\/h6>\n

rnYou can save up to 80%<\/strong> by choosing immunotherapy for ovarian cancer in India compared to the US.rnrnInterested in learning more about immunotherapy for other cancer types? Explore our comprehensive guide on immunotherapy for lung cancer in India<\/a>.rn<\/p>\n

Cost of Other Treatments for Ovarian Cancer in India<\/h3>\n

rnIn addition to immunotherapy, treatments for ovarian cancer in India include chemotherapy, radiation, and surgery. Chemotherapy costs between $250 and $300 per session, radiation therapy ranges from $4,500<\/strong> to $6,500<\/strong>, and surgery is $3,500.<\/strong>rnrnIn the US, these treatments can cost up to 95% more. See the following table for more details.rn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\nrn<\/p>\n
Treatment<\/strong><\/td>\n

rn<\/p>\n

Cost in India (USD)<\/strong><\/td>\n

rn<\/p>\n

Cost in the US (USD)<\/strong><\/td>\n

rn<\/p>\n

Savings<\/strong><\/td>\n

rn<\/tr>\n

rn<\/p>\n

Chemotherapy<\/td>\n

rn<\/p>\n

$250 – $300<\/strong> per session<\/td>\n

rn<\/p>\n

Up to $52,700<\/strong>\n

WebMD<\/p>\n

Ovarian Cancer: Cost of Medical Care and Treatment<\/strong><\/p>\n

'Outpatient services like chemotherapy ($52,700)'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[8]<\/sup><\/span><\/td>\n

rn<\/p>\n

95%<\/strong><\/td>\n

rn<\/tr>\n

rn<\/p>\n

Radiation Therapy<\/td>\n

rn<\/p>\n

$4,500 – $6,500<\/strong><\/td>\n

rn<\/p>\n

$9,000<\/strong> and up<\/td>\n

rn<\/p>\n

50%<\/strong><\/td>\n

rn<\/tr>\n

rn<\/p>\n

Surgery<\/td>\n

rn<\/p>\n

$3,500<\/strong><\/td>\n

rn<\/p>\n

$30,700<\/strong> and up\n

WebMD<\/p>\n

Ovarian Cancer: Cost of Medical Care and Treatment<\/strong><\/p>\n

'Inpatient services such as surgery and hospitalization after surgery ($30,708)'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[9]<\/sup><\/span><\/td>\n

rn<\/p>\n

90%<\/strong><\/td>\n

rn<\/tr>\n

rn<\/tbody>\n

rn<\/table>\n

rn<\/p>\n

*Prices are case-dependent.<\/h6>\n

rnCheck out our other articles to know the cost of immunotherapy for pancreatic<\/a> and colorectal cancer in India<\/a>.rn<\/p>\n

Source: WebMD<\/strong>\n

WebMD<\/p>\n

Ovarian Cancer: Cost of Medical Care and Treatment<\/strong><\/p>\n

'Outpatient services like chemotherapy ($52,700)'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[8]<\/sup><\/span>\n

WebMD<\/p>\n

Ovarian Cancer: Cost of Medical Care and Treatment<\/strong><\/p>\n

'Inpatient services such as surgery and hospitalization after surgery ($30,708)'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[9]<\/sup><\/span><\/p>\n

rn

Get affordable immunotherapy in India!<\/h2>

Connect with our consultants today<\/h3>Request FREE quote<\/a><\/div>rnrn\n

Overview of Immunotherapy for Cancer in India<\/h2>\n rnrnImmunotherapy helps the immune system fight cancer using lab-made substances similar to immune cells.rnrnRead the main article for more details on Immunotherapy for Cancer in India<\/a><\/strong>.rnrnIn a recent study, combining pembrolizumab with bevacizumab<\/strong> and oral cyclophosphamide<\/strong> showed a clinical benefit for 95%<\/strong> of patients with recurrent ovarian cancer. This treatment also provided long-lasting responses for 25%<\/strong> of these patients.\n

JAMA Network<\/p>\n

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial | Targeted and Immune Therapy<\/strong><\/p>\n

'In this phase 2 nonrandomized clinical trial, the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit in 95.0% and durable treatment responses (>12 months) in 25.0% of patients with recurrent ovarian cancer. '<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[10]<\/sup><\/span>rnrnAlong with this promising combination, there are different types of immunotherapy.rnrnIn the next section, we’ll explain each one.rn<\/p>\n

Source: JAMA Network\n

JAMA Network<\/p>\n

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial | Targeted and Immune Therapy<\/strong><\/p>\n

'In this phase 2 nonrandomized clinical trial, the combination of pembrolizumab with bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit in 95.0% and durable treatment responses (>12 months) in 25.0% of patients with recurrent ovarian cancer. '<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[10]<\/sup><\/span><\/strong><\/p>\n

rnrn<\/p>\n

Different Types of Immunotherapy<\/h3>\n

rnImmunotherapy offers various ways to fight cancer, each with its own approach:rnrnrnrnRest assured! After examining you, our expert oncologists in India will recommend the best immunotherapy for your specific needs.rn<\/p>\n

Source: Cancer\n

Cancer<\/p>\n

Treating Cancer with Immunotherapy<\/strong><\/p>\n

'Checkpoint inhibitors: These drugs basically take the u2018brakesu2019 off the immune system, which helps it recognize and attack cancer cells. Chimeric antigen receptor (CAR) T-cell therapy: This therapy takes some T-cells from a patient's blood, mixes them with a special virus that makes the T-cells learn how to attach to tumor cells, and then gives the cells back to the patient so they can find, attach to, and kill the cancer. Cytokines: This treatment uses cytokines (small proteins that carry messages between cells) to stimulate the immune cells to attack cancer. Monoclonal antibodies (mAbs or MoAbs): These are man-made versions of immune system proteins. mAbs can be very useful in treating cancer because they can be designed to attack a very specific part of a cancer cell.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[11]<\/sup><\/span><\/strong><\/p>\n

rn\n

Immunotherapy and Ovarian Cancer<\/h2>\n rnrnOvarian cancer occurs when abnormal cells in the ovary start to grow uncontrollably, eventually forming a tumor.\n

Cancer Research UK<\/p>\n

What is ovarian cancer?<\/strong><\/p>\n

'Ovarian cancer is when abnormal cells in the ovary begin to grow and divide in an uncontrolled way. And eventually form a growth (tumour).'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[12]<\/sup><\/span> Itu2019s the third most common gynaecological cancer, with about 300,000 new cases worldwide in 2020.\n

Cancer Research<\/p>\n

Immunotherapy for Ovarian Cancer<\/strong><\/p>\n

'Globally, ovarian cancer is diagnosed in an estimated 300,000 people each year, and causes roughly 180,000 deaths.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[13]<\/sup><\/span>rnrnFortunately, new treatments for ovarian cancer, like immunotherapy, provide more hope. Indian researchers combine different therapies to attack cancer cells and strengthen the immune system.rnrnFor example, using PARP inhibitors<\/strong> with immunotherapy drugs like Pembrolizumab<\/strong> has shown good results, controlling the disease in 73%<\/strong> of cases in studies.rnrnAnother approach targets a protein called VEGF-A<\/strong>, combined with PD-1 inhibitors<\/strong>, which has helped 95%<\/strong> of patients with recurrent ovarian cancer stay cancer-free for over a year.rnrnVaccines using dendritic cells to boost the immune system have also shown amazing results. In one small trial, 90%<\/strong> of patients treated with a special DC vaccine lived for at least three years.\n

Frontiersin<\/p>\n

Limitations and potential of immunotherapy in ovarian cancer<\/strong><\/p>\n

'The combination of PARP inhibitor (Niraparib) with anti-PD-1 (Pembrolizumab) showed a 73% disease control rate in pre-clinical study models of high-grade serous OC A combination of anti-PD-1 with Bevacizumab (anti-VEGF) reported a clinical benefit of about 95% in recurrent OC patients with a progression-free survival (PFS) of over 12 months A small phase I trial with 11 patients who received DC loaded with HER-2 derived peptide reported an overall 3-year survival rate of 90% (67). Furthermore, a DC vaccine with folate receptor-u03b1 peptide in advanced OC demonstrated a PFS of 39% without any grade 3 toxicity'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[14]<\/sup><\/span>rn<\/p>\n

Sources: Cancer Research UK<\/strong>\n

Cancer Research UK<\/p>\n

What is ovarian cancer?<\/strong><\/p>\n

'Ovarian cancer is when abnormal cells in the ovary begin to grow and divide in an uncontrolled way. And eventually form a growth (tumour).'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[12]<\/sup><\/span>, Cancer Research<\/strong>\n

Cancer Research<\/p>\n

Immunotherapy for Ovarian Cancer<\/strong><\/p>\n

'Globally, ovarian cancer is diagnosed in an estimated 300,000 people each year, and causes roughly 180,000 deaths.'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[13]<\/sup><\/span>, Frontiers in<\/strong>\n

Frontiersin<\/p>\n

Limitations and potential of immunotherapy in ovarian cancer<\/strong><\/p>\n

'The combination of PARP inhibitor (Niraparib) with anti-PD-1 (Pembrolizumab) showed a 73% disease control rate in pre-clinical study models of high-grade serous OC A combination of anti-PD-1 with Bevacizumab (anti-VEGF) reported a clinical benefit of about 95% in recurrent OC patients with a progression-free survival (PFS) of over 12 months A small phase I trial with 11 patients who received DC loaded with HER-2 derived peptide reported an overall 3-year survival rate of 90% (67). Furthermore, a DC vaccine with folate receptor-u03b1 peptide in advanced OC demonstrated a PFS of 39% without any grade 3 toxicity'<\/em><\/p>\n View in Article<\/a>\n <\/div>\n \">[14]<\/sup><\/span><\/p>\n

rn\n

Procedure: Complete Guide to Immunotherapy for Ovarian Cancer in India<\/h2>\n rnrnIn the previous section, we discussed how ovarian cancer affects the body and how immunotherapy can treat it.rnrnNow, you’ll learn everything you need to know about traveling to India for immunotherapy treatment of treat ovarian cancer.rnrnKeep reading!rn<\/p>\n

Plan Your Travel<\/h3>\n

rn<\/p>\n